3UGC

Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.34 Å
  • R-Value Free: 0.189 
  • R-Value Work: 0.176 
  • R-Value Observed: 0.177 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Andraos, R.Qian, Z.Bonenfant, D.Rubert, J.Vangrevelinghe, E.Scheufler, C.Marque, F.Regnier, C.H.De Pover, A.Ryckelynck, H.Bhagwat, N.Koppikar, P.Goel, A.Wyder, L.Tavares, G.Baffert, F.Pissot-Soldermann, C.Manley, P.W.Gaul, C.Voshol, H.Levine, R.L.Sellers, W.R.Hofmann, F.Radimerski, T.

(2012) Cancer Discov 2: 512-523

  • DOI: 10.1158/2159-8290.CD-11-0324
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Janus kinase (JAK) inhibitors are being developed for the treatment of rheumatoid arthritis, psoriasis, myeloproliferative neoplasms, and leukemias. Most of these drugs target the ATP-binding pocket and stabilize the active conformation of the JAK kinases ...

    Janus kinase (JAK) inhibitors are being developed for the treatment of rheumatoid arthritis, psoriasis, myeloproliferative neoplasms, and leukemias. Most of these drugs target the ATP-binding pocket and stabilize the active conformation of the JAK kinases. This type I binding mode can lead to an increase in JAK activation loop phosphorylation, despite blockade of kinase function. Here we report that stabilizing the inactive state via type II inhibition acts in the opposite manner, leading to a loss of activation loop phosphorylation. We used X-ray crystallography to corroborate the binding mode and report for the first time the crystal structure of the JAK2 kinase domain in an inactive conformation. Importantly, JAK inhibitor-induced activation loop phosphorylation requires receptor interaction, as well as intact kinase and pseudokinase domains. Hence, depending on the respective conformation stabilized by a JAK inhibitor, hyperphosphorylation of the activation loop may or may not be elicited.


    Organizational Affiliation

    Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase JAK2A295Homo sapiensMutation(s): 2 
Gene Names: JAK2
EC: 2.7.10.2
Find proteins for O60674 (Homo sapiens)
Explore O60674 
Go to UniProtKB:  O60674
NIH Common Fund Data Resources
PHAROS  O60674
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
046
Query on 046

Download CCD File 
A
5-{[6-(acetylamino)pyrimidin-4-yl]oxy}-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-2,3-dihydro-1H-indole-1-carboxamide
C28 H30 F3 N7 O3
VQLNKQZLPGLOSI-UHFFFAOYSA-N
 Ligand Interaction
MLI
Query on MLI

Download CCD File 
A
MALONATE ION
C3 H2 O4
OFOBLEOULBTSOW-UHFFFAOYSA-L
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.34 Å
  • R-Value Free: 0.189 
  • R-Value Work: 0.176 
  • R-Value Observed: 0.177 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 106.97α = 90
b = 69.39β = 98.98
c = 50.8γ = 90
Software Package:
Software NamePurpose
PHASERphasing
BUSTERrefinement
XDSdata reduction
XSCALEdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2012-05-16
    Type: Initial release
  • Version 1.1: 2012-07-04
    Changes: Non-polymer description
  • Version 1.2: 2012-08-29
    Changes: Database references
  • Version 1.3: 2018-04-11
    Changes: Data collection, Structure summary